Methods and compositions relating to microbial treatment and diagnosis of disorders
The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
1. A method of treating a metabolic disorder in a subject, the method comprising:
administering to the subject a composition comprising:
a) a first microbe comprising a 16S rRNA sequence comprising at least about 97% sequence identity to a 16S rRNA sequence of Akkermansia muciniphila;
b) a second microbe comprising a 16S rRNA sequence comprising at least about 97% sequence identity to a 16S rRNA sequence of Eubacterium hallii; and
c) a third microbe comprising a 16S rRNA sequence comprising at least 97% sequence identity to a 16S rRNA sequence of Clostridium beijerinckii;
thereby treating the metabolic disorder, wherein the metabolic disorder is selected from the group consisting of Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus, obesity, and insulin resistance.
2. The method of claim 1 , wherein the first microbe is Akkermansia muciniphila.
3. The method of claim 1 , wherein the composition further comprises a fourth microbe, wherein the fourth microbe comprises a 16S rRNA sequence that comprises at least about 97% sequence identity to a 16S rRNA sequence of a microbe selected from the group consisting of: Bifidobacterium infantis, Clostridium butyricum, Clostridium indolis, and Faecalibacterium prausnitzii.
4. The method of claim 1 , wherein the composition further comprises one or more of: Bifidobacterium infantis, Clostridium butyricum, Clostridium indolis , or Faecalibacterium prausnitzii.
5. The method of claim 1 , wherein the composition further comprises Bifidobacterium infantis.
6. The method of claim 1 , wherein the composition does not contain dairy.
7. The method of claim 1 , wherein the composition is administered daily.
8. The method of claim 1 , wherein the composition is administered at least twice daily.
9. The method of claim 1 , wherein the composition is in a form of a capsule.
10. The method of claim 1 , wherein the composition is a food composition in a form of a bar.
11. The method of claim 1 , wherein the metabolic disorder is Type 2 diabetes mellitus.
12. The method of claim 1 , wherein the second microbe is Eubacterium hallii.
13. The method of claim 1 , wherein the first microbe, the second microbe, or the third microbe has been grown substantially on plant-based media.
14. The method of claim 13 , wherein the plant-based media comprises an amino acid source that is a plant-protein hydrolysate.
15. The method of claim 1 , wherein the third microbe is Clostridium beijerinckii.
16. A method of treating a metabolic disorder in a subject, the method comprising:
administering to the subject a composition comprising:
a) a first microbe comprising a 16S rRNA sequence comprising at least about 85% sequence identity to a 16S rRNA sequence of Akkermansia muciniphila;
b) a second microbe comprising a 16S rRNA sequence comprising at least about 85% sequence identity to a 16S rRNA sequence of Eubacterium hallii; and
c) a third microbe comprising a 16S rRNA sequence comprising at least about 85% sequence identity to a 16S rRNA sequence of Clostridium beijerinckii;
thereby treating the metabolic disorder, wherein the metabolic disorder is selected from the group consisting of Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus, obesity, and insulin resistance.
17. The method of claim 16 , wherein the first microbe is Akkermansia muciniphila.
18. The method of claim 16 , wherein the composition is administered daily.
19. The method of claim 16 , wherein the composition is in a form of a capsule.
20. The method of claim 16 , wherein the composition is a food composition in a form of a bar.
21. The method of claim 16 , wherein the composition does not contain dairy.
22. The method of claim 16 , wherein the composition further comprises a fourth microbe, wherein the fourth microbe comprises a 16S rRNA sequence that comprises at least about 85% sequence identity to a 16S rRNA sequence from a microbe selected from the group consisting of: Bifidobacterium infantis, Clostridium butyricum, Clostridium indolis , and Faecalibacterium prausnitzii.
23. The method of claim 16 , wherein the composition further comprises Bifidobacterium infantis.
24. The method of claim 16 , wherein the metabolic disorder is Type 2 diabetes mellitus.
25. The method of claim 16 , wherein the composition further comprises one or more of: Bifidobacterium infantis, Clostridium butyricum, Clostridium indolis , or Faecalibacterium prausnitzii.
26. The method of claim 16 , wherein the second microbe is Eubacterium hallii.
27. The method of claim 16 , wherein the composition comprises at least 1×10 5 CFUs of the first microbe, the second microbe, the third microbe, or a combination thereof.
28. The method of claim 16 , wherein the third microbe is Clostridium beijerinckii.
29. The method of claim 16 , wherein the composition further comprises an excipient comprising a growth media, wherein the growth media is a substantially plant-based media.
30. The method of claim 29 , wherein the substantially plant-based media is in a powdered form in the composition.
31. The method of claim 29 , wherein the substantially plant-based media comprises an amino acid source that is a plant-protein hydrolysate.